CHINARES PHARMA (03320) has announced that its non-wholly owned subsidiary, China Resources Pharmaceutical Commercial Group Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate bonds in China. The issuance was conducted in accordance with the approval from the China Securities Regulatory Commission (Approval No. [2024]1356), which granted permission for the subsidiary to issue up to 20 billion yuan in corporate bonds to qualified investors in China.

The board of directors is pleased to confirm that the first tranche of the 2026 corporate bonds, with a total value of 1.8 billion yuan, has been successfully issued. These bonds have a maturity period of three years and carry an annual coupon rate of 1.70%.

The net proceeds raised from this bond issuance will be allocated for productive expenditures. These include supplementing working capital, repaying interest-bearing debts, funding project investments, and other purposes compliant with applicable laws and regulations.